Biofrontera Inc. (BFRIW)

Market Cap	7.56M
Revenue (ttm)	35.36M
Net Income (ttm)	-12.84M
Shares Out	7.75M
EPS (ttm)	-3.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,643
Open	0.0744
Previous Close	0.0999
Day's Range	0.0744 - 0.0744
52-Week Range	0.0744 - 0.0744
Beta	0.30
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 7, 2025

About BFRIW

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate seve...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2015
• Employees: 85
• Stock Exchange: NASDAQ
• Ticker Symbol: BFRIW
• Website: https://www.biofrontera-us.com

Financial Performance

In 2023, Biofrontera's revenue was $34.07 million, an increase of 18.82% compared to the previous year's $28.67 million. Losses were -$20.13 million, 3045.5% more than in 2022.